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INTRODUCTION: This is a second Pilot Study to determine the efficacy of Gleevec® in neurofibromatosis (NF1) patients with plexiform neurofibromas using new response assessment modalities with the secondary goals of assessing Gleevec toxicity, and characterizing markers of response. The rationale for this study arises from the response of human and murine NF1 cells to Gleevec® in vitro, the response of a NF1 patient treated with Gleevec® for airway compression by a plexiform neurofibroma with a dramatic response not previously seen in NF1 therapy, and the experience in 37 NF1 patients treated with Gleevec® in the initial pilot study. Twenty one patients were enrolled including 8 pediatric patients. Four were inevaluable and 17 were evaluable completing at least 6 months of treatment owing to the success of a dose escalation schedule for individual patients. Primary endpoint MRI's, and secondary endpoints safety monitoring, circulating cytokines and endothelial progenitor cell assays, and quality of life data were obtained from evaluable patients. Proposed biopsies, pressure measurements, and PET imaging were not indicated in the enrolled patients. Results from each of the secondary endpoint assays have been completed and await final MRI measures which are in progress. Once MRI measures have been completed, they will be correlated with each of the secondary measures with anticipation of completion by the end of this calendar year.
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ACCOMPLISHMENTS:
What were the major goals of the project?
The goal of this Pilot Study is to trial and develop multiple techniques for determining the response of NF1 patients with plexiform neurofibromas to Gleevec® therapy for use in subsequent clinical trials. The impact of this proposal is having a better way to measure/quantify the response of plexiform neurofibromas in NF1 patients to treatment. a. Finalize Protocol submit and receive approval from Indiana School of Medicine SRC, RSC, IRB, and Novartis approval (Months 1-6). b. Submission and approval of locally approved protocol to HRPO (Months 6-9). c. Identify prospective NF1 patients for enrollment upon approval (Months 1-9). The protocol was submitted to the Indiana University Cancer Center Scientific Review board on July 31, 2009 with approval on Oct 7, 2009 . The protocol was also submitted to the Indiana University Institutional Review Board on July 31, 2009 and approved 10/29/2009. These documents were submitted to the DOD on 11/2009. We received the DOD provisions on 1/19/2010 and returned the response to the provisions on 2/18/2010. The protocol was amended to include the provisions from the DOD and Novartis and submitted to our IRB 3/16/2010. We received IRB approval of Amendment #1 on 3/29/2010. We received final DOD approval 6/4/2010. We enrolled our first subject on 6/30/2010. Because of slow enrollment, we applied and obtained an amendment to enroll pediatric patients. We have enrolled a total of 21 patients with amending the study to include pediatric patients. We received a no-cost extension to complete enrollment of the pediatric cohort. The last patient was enrolled on 02 June 2014 with last patient visit was on 22-JUN-2015. High resolution flow cytometry data for endothelial progenitor cells was collected real time. Cytokine analysis of all samples were run together and began in May 2015 and completed assays in May 2016 with change from ELISA format to EMD Millipore Multiplex. Quality of Life (QOL) data analysis was completed April 2016. The Indiana IRB approved a renewal on 21-Jul-2016, closed to enrollment, for data analysis. MRI analysis is ongoing and upon completion will be used to correlate response with endothelial cell progenitor populations, cytokines, and QOL as potential measures of response.
What was accomplished under these goals?
1. Enrollment. Approval and initiation of enrollment was accomplished in a timely manner. However, over time enrollment was slow. To approach this problem, we submitted an amendment to allow treatment of children resulting in our last 8 patients enrolled being children. 2. Real time high resolution flow cytometric evaluation of circulating endothelial progenitors.
A. Enrollment Timing

Flow for Endothelial Progenitor Cells
EPCs are being studied as surrogate markers for multiple vascular pathologies in adults. However, data interpretation has been difficult because of inconsistent definitions and methodologies used to enumerate these rare circulating cells. Flow cytometry has been used to identify and enumerate circulating EPC subpopulations as outlined below. Specifically, Duda et. al. standardized, in a recent Nature Protocols paper, a flow cytometry-based method for enumerating specific EPC populations in blood that serve as biomarkers for vascular disease risk and response to anti-angiogenic therapies in human cancers. MNCs are stained with antibodies directed against endothelial and progenitor cell-specific antigens. Viable MNCs are analyzed for CD34+CD133+CD45dimCD31+, circulating progenitor cells (CPCs) and CD34+CD45-CD31+CD133-, circulating endothelial cells (CECs), which correlate with disease progression in various pathologies. However, no previous studies have been conducted in patients with NF1. Examination of these cell types is important, especially in patients with plexiform nuerofibromas, as these cells types may potentiate angiogenesis.
The Angiogenesis and Endothelial Progenitor Cell Core at Indiana University, directed by Dr. Ingram, developed a standardized 5-color flow cytometry method based on recent studies by Duda et. al. The first fluorescent channel is a "dump channel", which is used to exclude nonviable cells, red blood cells, and platelets from analysis. This is a key step since contamination with these cell populations can significantly alter the accuracy of the data generated, especially when rare populations are analyzed. The remaining 4 antigens examined are CD34 and CD133 (stem and progenitor cell antigens), CD45 (hematopoietic cell antigen), and CD31 (endothelial cell antigen). Gating strategies are illustrated below.
Flow Cytometric Method:
A 5-color flow cytometry assay will be conducted similar to preliminary studies. MNCs will be stained with antibodies against cell surface antigens, CD34, CD133, CD31, and CD45, as well as a viability marker, CD41a, and glycophorin A for the exclusion of dead cells, platelets, and red blood cells, respectively. Fluorescence minus one (FMO) controls will be prepared as negative gating controls. The frequency of phenotypically defined cell populations will be analyzed using an LSR II flow cytometer and FlowJo software. Data has been obtained for all 21 patients. Multiple time points were obtained in all but 3 patients. Time points were assayed as available at baseline, 2-3 weeks, and 6 months of Gleevec therapy. Of some interest, patients developing edema had a large increase in their circulating progenitor cell CPC ratio in a short period. Additionally, one patient with an airway tumor had a significant increase in their CPC ratio over time after a stable ratio from baseline and 2 weeks. Data will be correlated with MRI response data to see if trends in CPC ratios correlate with or are predictive of response (better or worse).
Bio-Plex Circulating Cytokine Analysis.
Funds unused from tumor biopsy immunohistochemistry were used to expand the number of circulating cytokines assayed and change from the more expensive ELISA based assay to the more economical Millipore Bio-Plex system. Part of the incentive to expand this panel came from data in our initial pilot study with Gleevec in NF1 plexiforms using a 15 cytokine ELISA panel which demonstrated that a greater than two-fold increase in certain Samples were aliquoted for each kit and had 2 freeze/thaw cycles to keep the freeze/thaw variable consistent throughout all kits and plates. Samples were aliquoted due to some samples only have 1-2 vials of plasma. Therefore 1 vial was thawed and the plasma was aliquoted into new, sterile, tubes for each kit. Each new aliquot was then frozen until ready for use. All samples have been assayed. Data will be correlated with MRI response data to see if trends in circulating cytokines, cytokine receptors, TGF, and SCF correlate with or are predictive of response to therapeutic intervention.
Quality of Life (QOL) Analysis.
Adult QOL was measured using the SF 36. This instrument is a modular instrument for measuring health-related QOL in adults. The SF 36 Core Scales are multidimensional selfreport scales developed as a generic core measure of QOL. The SF 36 Core Scales measure physical functioning, emotional functioning, social functioning. Validity of the SF 36 Core Scales was established by known group comparisons and correlations with other measures of disease burden. Reliability was established by internal consistency reliability. Alpha coefficients for selfreport were greater than 0.90. Item response distributions were across the full-scale range, with no floor effects and minimal ceiling effects. The Pediatric Quality of Life Inventory (PedsQL) tool is designed to measure health-related quality of life in children and adolescents aged 2-18 years. In our study, the Pediatric QOL evaluation was performed using the PedsQL tool in 5 pediatric patients: is in characterizing the fluid dynamics and potential for drug perfusion of plexiform tumors that have developed a more extensive collagenous or vascular microenvironment which can impact drug delivery. Tumor tissue is often difficult to distinguish from normal structures, but applying a neural network multispectral classification plot for segmentation can allow differentiation between normal and tumor tissue by differences in their very different slopes:
Gleevec Trial PedsQL Generic Core Scales
In the next 2 sets of images, we pulled together representative cases for the NF1 tumors pre and post Gleevec treatment. The left of each of these images is the B0 DWI MRI to show anatomy and the right is the same image with the tumors highlighted in fuchsia/pink. These tumors although not always smaller do seem to have difference appearance (less textured) in the post treatment groups. At the current time, we can't say much about the volumes for these as we have not finished the analysis and statistics, but this will be forthcoming soon. In addition, we plan to use all 7 B-value DWI images and compute the IVIM diffusion model for these same subjects. This will tell us if the molecular composition of the tumor has changed with respect to Tumor DWI (B0) diffusion and tissue perfusion. Our hope is that this measure may provide valuable insights into the changes that Gleevec can have on NF1 tumors which may be independent of tumor volumes. Volumetric data generated will be correlated with cytokine, EPC, and QOL data to determine impact of tumor response on other measures of response. determining the response of NF1 patients with plexiform neurofibromas to Gleevec therapy for use in subsequent clinical trials. The impact of this proposal is having a better way to measure/quantify the response of plexiform neurofibromas in NF1 patients to therapies to identify which treatments will work to benefit patients to the greatest extent. These methods of measurement provide a way to ask with each clinical trial, how can we make NF1 plexiform neurofibromas respond better.
Neurofibromatosis Pre and Post Gleevec (NF13) Neurofibromatosis Pre and Post Gleevec (NF17)
What was the impact on other disciplines? Potential application of these measures in other tumor systems.
What was the impact on technology transfer? Nothing to report.
What was the impact on society beyond science and technology?
Plexiform tumors are among the most frustrating tumors to treat because they respond so poorly to conventional chemotherapy and produce chronic pain and slow progressive impingement on normal organs which in some cases are life threatening. By improving therapy for these awful tumors, we can move toward an improved the quality of life in patients with neurofibromatosis that occur in one in 3500 people.
CHANGES/PROBLEMS:
Changes in approach and reasons for change. The plexiform tumors encountered in this study did not present as indications for biopsy which precluded the immunohistochemical tissue studies. These resources were utilized for an expanded cytokine array as an economical and efficient method to probe the activity and response of plexiform tumors to Gleevec.
Actual or anticipated problems or delays and actions or plans to resolve them. Because of slow accrual, an amendment was submitted and approved by the DOD and IRB to allow enrollment of pediatric patients which significantly improved enrollment allowing completion of the study.
Changes that had a significant impact on expenditures . As above. What other organizations were involved as partners? Nothing to report.
SPECIAL REPORTING REQUIREMENTS
COLLABORATIVE AWARDS: Nothing to report.
QUAD CHARTS: Nothing to report.
